Pair of high-profile cancer drugs may come to market

12/5/2003 | Forbes

Two new drugs to treat colon cancer are expected to get FDA approval next year: Erbitux is being developed by Imclone Systems and Bristol-Myers Squibb, and Genentech is developing Ivastin. Both drugs slow the growth of tumors by attacking key proteins.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY